White Paper - Companion Diagnostic Development: An Overview Xenium In Situ Services are Now Available Improving Pathology Precision in Oncology: How AI Reduces Variability in Tumor Percent Assignments Advancing In Vitro Disease Modeling with Mouse Hepatocytes for Gene Therapy

ctDNA NGS
Trusight™ Oncology 500
(TSO500)

Reduce time to develop and validate your oncology liquid biopsy research and diagnostic assay development by utilizing our TSO500 ctDNA application to detect ctDNA genomic variants and biomarker signatures

Discovery Genomics' TSO500 ctDNA NGS service provides high sensitivity detection of genomic variants across 523 DNA genes in various cancer indications from liquid biopsy plasma samples, including microsatellite instability (MSI) and tumor mutational burden (TMB) immuno-oncology biomarkers.

Applications

Our TSO500 NGS services provide pan-cancer genomic biomarker analysis to enable:

Discovery and verification of the presence of genomic biomarker targets and signatures in liquid biopsy ctDNA
Retrospective identification of potential oncology clinical trial patient responders versus non-responders based on genomic profiles
RUO development and orthogonal validation of novel liquid biopsy diagnostic solutions
Combine the matching TSO500 Solid Tumor and TSO500 ctDNA applications to develop and validate non-invasive liquid biopsy assays from matched-patient Plasma and FFPE samples

Service Performance Data

Using commercially available reference standards in our optimized and automated nucleic acid extraction, library construction, and sequencing workflows, we demonstrate the accuracy, sensitivity, and reproducibility of our TSO500 Solid Tumor NGS RUO service.

LIMIT OF DETECTION:

> 1% Allele Fractions

ACCURACY:

>99%

ctDNA / Solid Tumor Concordance:

>99%

TSO500 ctDNA NGS Services Deliverables

TSO500 ctDNA v1.0.1 Output files

DNA Results

QC and Metrics Files

Sample Input Requirements

Blood collection tubes should be EDTA or Streck tubes, no Heparin tubes allowed
Plasma samples should be collected and separated within 2 hours of collection if possible as longer times impact degradation and downstream sequencing success. Double spun plasma is also acceptable.
1 - 2 mL plasma frozen at -80°C with no signs of hemolysis
ctDNA extractions from Plasma will be done using the Beckman Coulter Apostle MiniMax ctDNA Extraction Kit with automated extractions performed on the Beckman i7 robot
ctDNA QC will be performed on the Fragment Analyzer
ctDNA Input: >30 ng in 50 ul volume
NGS sequencing runs using paired end 2 x 150 base pair reads

ctDNA NGS Trusight™ Oncology 500 (TSO500)

Discovery Genomics' TSO500 ctDNA NGS service provides high sensitivity detection of genomic variants across 523 DNA genes in various cancer indications from liquid biopsy plasma samples, including microsatellite instability (MSI) and tumor mutational burden (TMB) immuno-oncology biomarkers.

Applications

Service Performance Data

LIMIT OF DETECTION:

> 1% Allele Fractions

ACCURACY:

>99%

ctDNA / Solid Tumor Concordance:

>99%

TSO500 ctDNA NGS Services Deliverables

Horizon OncoSpan cfDNA Reference Standard Sample Report

PierianDx Colon Carcinoma Sample Report

TSO500 ctDNA v1.0.1 Output files

DNA Results

QC and Metrics Files

Sample Input Requirements

Related Products & Services

FFPE and Other Oncology Specimens

Optimized Dual DNA/RNA Extraction Services

Molecular Pathology Services

TSO500 Solid NGS Services

Other Sequencing Services

Contact Us Today

Gentest Services

MARKETS WE SERVE

COMPANY

Markets We Serve

Resources

Popular Keywords

Categories,Pages

Quick Links

Technologies

Development and Clinical Trial Solutions

Our Mission

Technologies

Development and ClinicalTrial Solutions

Post-Approval Services

ctDNA NGS
Trusight™ Oncology 500
(TSO500)

TSO500 Solid
NGS Services

Other Sequencing
Services

Development and Clinical
Trial Solutions

Development and Clinical
Trial Solutions